Liaison(s): Carolina Amador, Yewande Pearse
Amgen Inc., headquartered in Thousand Oaks, California, is one of the largest biopharmaceutical companies in the United States. The company was founded as Applied Molecular Genetics in 1980 with the goal of manufacturing innovative medicines for seriously ill patients. Riding off successes of keys assets like Enbrel® (etanercept), Neulasta® (pegfilgrastim), and Prolia® (denosumab) in recent years, Amgen now consistently brings in over $20B in revenue annually. The TMP students will tackle a digital neurology landscape analysis to provide Amgen’s commercialization team with a full breath analysis of the external digital neurology space. This project supports Amgen’s Commercial Insights team focusing on their migraine drug Aimovig® (erenumab-aooe).
Aimovig® is a preventative migraine medication administered through injection (SC). In the broad neurology space, it is common for neurologists to treat a variety of conditions, such as, migraines, Alzheimer’s, strokes, Parkinson’s, multiple sclerosis, epilepsy, and others. Broadly researching the digital behavior of neurologists could help identify potential market opportunities for any of these conditions.
The digital neurology analysis consists of three simultaneously conducted phases: investigating the prevalence of digital prescriptions, external companies’ social media initiatives, and other digital media streams being utilized to target patients and healthcare professionals. As graduate and undergraduate students, we were uniquely positioned with generational knowledge to delve into these topics and provide maximum value to Amgen.
Celebrating 25 years of innovation! 25.kgi.edu.